Becton, Dickinson and Company (BDX) Stock Price & How to Invest

Last updated November 2026

Short answer

BDX is Becton, Dickinson and Company, a large American medical technology maker of syringes, catheters, infusion systems, prefillable drug-delivery devices and vascular products, and you can buy it or fractional shares at any major broker, hold it inside a healthcare or medical-devices ETF, or size it as one position in a medtech basket. The single most important fact for anyone researching BDX in 2026 is that this is no longer the same company as a year ago: BD completed the separation of its Biosciences and Diagnostic Solutions business into Waters Corporation on February 9, 2026, so the listed company today is a smaller, pure-play medtech built on consumable, high-volume hospital products. As of October 16, 2026 the shares closed at about $192.50, up roughly 26% year to date and 32% over one year, near the top of their 52-week range, for a market value of about $52 billion. Fiscal fourth-quarter results are due on November 5, 2026.

BDX stock price

As of 2026-11-16, Becton, Dickinson and Company (BDX) last closed at $216.47, up 44.2% over the past year. Over the past 52 weeks it has traded between $140.71 and $218.03.

BDX last close
$216.47
1 day
-0.72%
1 month
+12.89%
1 year
+44.18%
52-week range
$140.71 to $218.03
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Becton, Dickinson and Company's investor relations page. Walnut is informational, not investment advice.

BDX key stats

At $216.47 on November 16, 2026, Becton, Dickinson and Company (BDX) has a market cap of $59.0B, a P/E of 42.8 on trailing earnings (15.2 on forward earnings) and a dividend yield of 1.96%.

Market cap
$59.0B
P/E (trailing)
42.8
P/E (forward)
15.2
EPS (trailing 12 months)
$5.06
Price to book
2.4
Dividend yield
1.96%
Beta
0.28

Market cap, P/E and yield are measured at the $216.47 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Becton, Dickinson and Company (BDX)?

The last two weeks for Becton, Dickinson and Company, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • BDX closed at $216.47 on November 16, 2026, up 0.6% over the past five trading days (from $215.25).
  • On November 5, 2026, Becton, Dickinson and Company filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 10, 2026, Barclays raised its target to $195.00 from $165.00 (Underweight).
  • On November 7, 2026, JP Morgan raised its target to $202.00 from $170.00 (Neutral).
  • On November 6, 2026, Citigroup raised its target to $241.00 from $208.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Becton, Dickinson and Company (BDX) do?

Becton, Dickinson and Company, known as BD, is one of the largest medical technology companies in the world, founded in 1897 and headquartered in Franklin Lakes, New Jersey. Most of what it sells is consumable rather than capital equipment: needles and syringes, IV catheters and vascular access sets, infusion pumps and their disposable sets, surgical and specimen-collection products, prefillable syringes sold to pharmaceutical companies, and interventional devices used in urology, peripheral vascular and surgery. That mix matters because consumables are consumed and reordered, so a large share of revenue recurs each year regardless of hospital capital budgets. Following the February 2026 separation, BD reports in four segments: Medical Essentials (~$1.68 billion in the June 2026 quarter), Interventional (~$1.41 billion), Connected Care (~$1.22 billion) and BioPharma Systems (~$0.67 billion).

The defining corporate event was the Reverse Morris Trust transaction that moved BD's Biosciences and Diagnostic Solutions businesses into Waters Corporation, which closed on February 9, 2026. BD shareholders received roughly 0.135 shares of Waters for each BD share held as of February 5, 2026 and ended up owning about 39.2% of the combined Waters, while BD itself received about $4 billion in cash. The divested business was valued at roughly $18.8 billion. Anyone comparing BDX financials across periods needs to be careful, because the separated business is now reported as discontinued operations: trailing revenue from continuing operations sits near $20.8 billion, while pre-separation fiscal 2025 revenue as originally reported was about $21.8 billion. In the third quarter of fiscal 2026, reported on August 6, 2026, BD posted about $5.0 billion of revenue (up ~5.4% as reported and ~4.4% on a currency-neutral basis), GAAP diluted EPS from continuing operations of ~$1.64 and adjusted diluted EPS of ~$3.23, and raised the top end of its full-year adjusted EPS guidance to a range of ~$12.62 to ~$12.72.

The market has rewarded the simpler company. As of October 16, 2026 BDX closed at about $192.50, up about 25.6% year to date, about 25% over three months and about 32% over one year, close to its 52-week high of roughly $196 (the 52-week low was about $128). Adjusted EPS has beaten consensus in each of the last four quarters, most recently $3.23 against about $3.14 for the June quarter. In October BD also reported nine-month AGILITY trial data for its Revello stent in peripheral artery disease, a pipeline item for the Interventional segment. The company reports fiscal fourth-quarter and full-year 2026 results on November 5, 2026, with consensus at about $5.1 billion of revenue and $4.07 of adjusted EPS.

What's driving Becton, Dickinson and Company (BDX)?

1. A simpler, pure-play medtech after the Waters separation

The whole point of the February 2026 separation was to leave behind a focused medical technology company rather than a conglomerate spanning devices, life-science research tools and diagnostics. Management argues the remaining portfolio has more consistent growth, better cash conversion and a cleaner story for investors, and the ~$4 billion of cash received gives room for debt paydown and buybacks. The test over the next several quarters is whether the residual company actually delivers the mid-single-digit organic growth and margin expansion that justified breaking the company up.

2. BioPharma Systems and injectable drug delivery

BioPharma Systems makes prefillable syringes, pens and self-injection systems sold to pharmaceutical customers, which puts BD in the supply chain for the GLP-1 obesity and diabetes drugs and for the broader shift toward biologics delivered by injection at home. This segment grew about 6.6% as reported in the June 2026 quarter, the fastest of the four. The flip side is customer concentration: a small number of very large pharma buyers drive the order book, and their capacity and inventory decisions move BD's results.

3. Interventional and Connected Care growth platforms

Interventional (peripheral vascular, urology, surgery) and Connected Care (infusion systems, medication management, dispensing) are the segments BD points to for above-portfolio growth, and both grew in the mid-single digits in the June 2026 quarter. Connected Care in particular benefits from the return of the Alaris infusion pump to the US market after the long FDA remediation, which converts a former liability into a placement and consumables opportunity. Recurring disposable sets attached to installed pumps are the durable part of that economics. In October 2026 BD reported nine-month AGILITY trial results for the Revello stent in peripheral artery disease, one more clinical data point for the Interventional growth story.

4. Valuation reset and capital returns

After a roughly 26% rise in 2026, BDX trades near ~$192.50 per share for a market capitalization around ~$52 billion, or roughly 14.5 times forward earnings, still a discount to higher-growth device peers but a narrower one than earlier in the year. The company pays a dividend of ~$4.20 per share (a yield near ~2.2% at the higher price) and has a long record of annual increases. Whether the discount narrows further depends on management sustaining organic growth and free cash flow now that the portfolio-reshaping story is done.

What are the risks to Becton, Dickinson and Company (BDX)?

The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. Quality and regulatory risk is real and recurring for a device maker at this scale, including a 2026 voluntary recall of certain intraosseous vascular access needle sets and the multi-year FDA remediation history of the Alaris infusion pump. Customer power is a structural pressure, because hospitals buy through group purchasing organizations and integrated delivery networks that negotiate hard on commodity consumables such as syringes and catheters, while China volume-based procurement compresses pricing in that market. Tariffs, freight and input costs affect a business that ships enormous physical volumes across borders, and currency swings move reported results given large international exposure. Finally, the separation itself introduces execution risk: stranded costs, dis-synergies and a smaller revenue base against the debt taken on before the split all have to be managed, and the comparison history is now discontinuous, which makes trend analysis harder. After a 25% three-month rally to near its 52-week high, the stock also carries more expectation than it did earlier in 2026, so a soft fiscal 2027 outlook on November 5 would land on a fuller valuation.

What is the Becton, Dickinson and Company (BDX) forecast?

14 analysts publish price targets on BDX, averaging $226.14 as of November 2026, or +4.5% against the $216.47 share price on November 16, 2026. The published targets run from $195.00 to $242.00, a narrow spread, and the ratings split 9 buy, 6 hold, 1 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BDX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is BDX a buy or a sell?

We give no verdict on Becton, Dickinson and Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. A simpler, pure-play medtech after the Waters separation. The whole point of the February 2026 separation was to leave behind a focused medical technology company rather than a conglomerate spanning devices, life-science research tools and diagnostics. The most optimistic published target, $242.00, assumes this works close to its best case.

The case against. The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. The most pessimistic target, $195.00, is roughly what BDX is worth if this bites instead.

Read the full bull and bear case on BDX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Becton, Dickinson and Company (BDX) split its stock?

Yes. Becton, Dickinson and Company (BDX) has had 2 share splits in the last 10 years:

  • 1025:1000 on April 1, 2022, so every share held became 1.025 shares.
  • 1272:1000 on February 10, 2026, so every share held became 1.272 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of BDX the day before the 1272:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

How is Becton, Dickinson and Company (BDX) valued?

Market cap, P/E and dividend yield at today's price are in the BDX key stats above. The business figures below come from Becton, Dickinson and Company's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM, continuing operations): ~$20.8 billion
  • Q3 fiscal 2026 revenue (quarter ended June 2026): ~$5.0 billion, up ~5.4% as reported and ~4.4% currency-neutral
  • Q3 fiscal 2026 EPS: ~$1.64 GAAP diluted from continuing operations, ~$3.23 adjusted (vs ~$3.14 estimate)
  • Fiscal 2026 guidance (adjusted diluted EPS): ~$12.62 to ~$12.72
  • Margins (gross / operating): ~47% / ~16%
  • Dividend: ~$4.20 per share, yield ~2.2%

As of October 2026: All figures are approximate and tied to the asOf date; check live numbers before acting on any of them. The wide gap between the trailing GAAP multiple (~45x) and the forward multiple (~14.5x) is mostly an artifact of separation charges, intangible amortization and discontinued-operations accounting depressing reported GAAP earnings, which is why BD and most analysts discuss adjusted EPS. The stock's 2026 rally has lifted the forward multiple from about 13-14x in August toward 14.5x, and fiscal fourth-quarter results with a likely first look at fiscal 2027 arrive on November 5, 2026.

Which ETFs hold Becton, Dickinson and Company (BDX)?

If you want BDX exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in BDXExpense ratio
NOBLProShares S&P 500 Dividend Aristocrats ETF1.76%0.35%
SDYState Street SPDR S&P Dividend ETF1.5%0.35%

Who competes with Becton, Dickinson and Company (BDX)?

Hospital consumables and medication delivery

Baxter International, ICU Medical, Teleflex, Fresenius Kabi and privately held B. Braun compete directly across IV therapy, infusion pumps and sets, vascular access and syringes. This is BD's largest revenue pool and the most price-competitive, because hospitals buy these products in bulk through group purchasing organizations. Cardinal Health and Owens and Minor also compete in parts of the commodity medical-supply category while simultaneously distributing BD products.

Interventional and vascular devices

Boston Scientific, Medtronic, Teleflex, Merit Medical and Cook Medical overlap with BD's Interventional segment in peripheral vascular, urology and surgical devices. These rivals generally grow faster and trade at higher multiples than BD's consumables base, which is part of why BD's overall valuation sits below the device-sector average. Competition here is driven by clinical evidence and physician preference rather than purchasing-department price lists.

Prefillable drug-delivery systems

West Pharmaceutical Services, Stevanato Group, Gerresheimer and SCHOTT Pharma compete with BD BioPharma Systems in prefillable syringes, cartridges, pens and containment components sold to pharmaceutical manufacturers. This group is levered to the same injectable-biologics and GLP-1 demand that BD cites as a growth driver. It is also where BD's customer concentration risk is highest, since a handful of large pharma companies set the volumes.

What stocks are similar to Becton, Dickinson and Company (BDX)?

Other names that sit close to BDX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Becton, Dickinson and Company (BDX)

There are three common ways to get BDX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (NOBL, SDY), which spreads the position across many companies. Or build it into a focused thematic portfolio, so BDX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BDX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Becton, Dickinson and Company (BDX)

Post-separation BD is a slower-growing but highly recurring medtech consumables business. After a roughly 26% gain in 2026 it trades near 14.5 times forward earnings, still below faster-growing device peers, so the debate is whether a simpler portfolio and a mid-single-digit organic growth rate justify a further narrowing of that discount, with the November 5 fiscal year-end report as the next checkpoint.

More on Becton, Dickinson and Company (BDX)

Whether BDX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BDX a buy or a sell?, and where the stock could go from here in the BDX stock forecast.

For income investors, whether BDX pays a dividend and how the payout looks is covered in does BDX pay a dividend? And to weigh BDX against a peer, read the full side-by-side comparisons: BDX vs BAX and BDX vs ICUI.

Wondering how BDX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Becton, Dickinson and Company

Ask Walnut's AI anything about BDX and see how it fits what you own.

FAQ

What company is BDX stock?

+

BDX is the New York Stock Exchange ticker for Becton, Dickinson and Company, usually called BD. It is a medical technology company founded in 1897 and based in Franklin Lakes, New Jersey, that makes syringes, needles, IV catheters, infusion systems, prefillable drug-delivery devices and interventional products. After the February 2026 separation it operates in four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.

Did Becton Dickinson spin off its diagnostics business?

+

Yes. BD completed the separation of its Biosciences and Diagnostic Solutions businesses and their combination with Waters Corporation on February 9, 2026, structured as a Reverse Morris Trust. BD shareholders received about 0.135 shares of Waters for each BD share held as of February 5, 2026 and ended up owning roughly 39.2% of the combined company, while BD received about $4 billion in cash. The divested business was valued at roughly $18.8 billion.

Is BDX a good stock to buy right now?

+

That depends on your goals, time horizon and risk tolerance, and nothing here is investment advice. The constructive case is a simpler post-separation medtech with heavily recurring consumables revenue, mid-single-digit organic growth, roughly 14.5 times forward earnings after a ~26% gain in 2026 and a long dividend record. The cautious case is slow growth against faster-growing device peers, persistent mesh and IVC-filter product liability, hospital pricing pressure and the execution risk of standing up a smaller company. Weigh both against the rest of your portfolio.

How much revenue does BD make?

+

Trailing twelve-month revenue from continuing operations is roughly $20.8 billion as of the quarter ended June 2026. The June 2026 quarter alone was about $5.0 billion, up roughly 5.4% as reported. Pre-separation fiscal 2025 revenue as originally reported was about $21.8 billion, but that figure included the Biosciences and Diagnostic Solutions business that is now part of Waters, so the two numbers are not directly comparable.

Does BDX pay a dividend?

+

Yes. BD pays a quarterly dividend that annualizes to about $4.20 per share, a yield near 2.2% at a share price around $192.50 as of October 2026. BD has a long history of consecutive annual dividend increases, which is part of why it appears in dividend-growth screens and dividend-focused ETFs. Dividends are declared quarterly by the board and are never guaranteed, so check the latest declaration before relying on any payout.

Why is BDX stock down or underperforming?

+

The stock has traded at a discount to faster-growing medical device peers for several years. Behind that discount sit mid-single-digit organic growth, exposure to price-pressured hospital consumables, China volume-based procurement, tariff and currency headwinds, and the overhang from mesh and IVC-filter litigation. The multi-year FDA remediation of the Alaris infusion pump also weighed on sentiment. Activist pressure in 2025 was one catalyst behind the decision to separate the Biosciences and Diagnostics segments. The share price turned in 2026: as of October 16 the shares were up about 26% year to date and about 32% over one year, as investors warmed to the post-separation company.

Is there a securities class action against Becton Dickinson?

+

There is no known active securities-fraud class action as of October 2026. The prior case, filed in 2020 in the US District Court for the District of New Jersey (Kabak v. Becton, Dickinson and Company, Civ. No. 2:20-cv-02155, later captioned Industriens Pensionsforsikring v. Becton, Dickinson and Company) over disclosures about the Alaris infusion pump, was resolved through an $85 million settlement that the court approved on April 22, 2024. Separately, BD faces substantial ongoing product-liability litigation over hernia mesh, pelvic mesh and IVC filters, which is disclosed in its SEC filings.

What ETFs hold BDX?

+

BDX is a component of broad S&P 500 index funds and of healthcare sector ETFs such as the Health Care Select Sector SPDR (XLV) and Vanguard Health Care (VHT), plus medical-device-focused funds like iShares US Medical Devices (IHI) and various dividend-growth ETFs. Fund exposure spreads single-stock risk but usually means BDX is only a fraction of a percent to a few percent of the fund. Check a fund's current holdings and weights before assuming meaningful exposure to BD specifically.

How did BD do in its latest quarter?

+

In its fiscal third quarter (ended June 2026), BD reported about $5.0 billion of revenue, up roughly 5.4% as reported, and adjusted EPS of $3.23 versus a consensus near $3.14, its fourth straight beat. It raised the top of its fiscal 2026 adjusted EPS guidance to ~$12.62-12.72. Fiscal fourth-quarter results are scheduled for November 5, 2026.

How has BDX stock performed in 2026?

+

As of October 16, 2026 BDX closed at about $192.50, up about 25.6% year to date and about 32% over one year, near the top of a 52-week range of roughly $128-196. The average analyst price target in Yahoo Finance's data is about $194, close to the current price. Walnut is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Becton, Dickinson and Company's investor relations page or your broker before making investment decisions.